מדינה: אירלנד
שפה: אנגלית
מקור: HPRA (Health Products Regulatory Authority)
PANTOPRAZOLE
Ranbaxy (UK) Limited
20 Milligram
Tablets Gastro-Resistant
2009-03-13
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Pantoprazole Ranbaxy 20 mg gastro-resistant tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each gastro-resistant tablet contains 20 mg pantoprazole (as pantoprazole sodium sesquihydrate 22.6 mg). For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Gastro-resistant tablet. Yellow enteric coated oval shaped, biconvex tablets imprinted with ‘II’ on one side and plain on other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Adults and adolescents 12 years of age and above Symptomatic gastro-oesophageal reflux disease. For long-term management and prevention of relapse in reflux oesophagitis. Adults Prevention of gastroduodenal ulcers induced by non-selective non-steroidal anti-inflammatory drugs (NSAIDs) in patients at risk with a need for continuous NSAID treatment (see section 4.4). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Tablets should not be chewed or crushed, and should be swallowed whole 1 hour before a meal with some water. Recommended dose: Adults and adolescents 12 years of age and above: Symptomatic gastro-oesophageal reflux disease The recommended oral dose is one gastro-resistant tablet Pantoprazole Ranbaxy 20 mg per day. Symptom relief is generally accomplished within 2-4 weeks. If this is not sufficient, symptom relief will normally be achieved within a further 4 weeks. When symptom relief has been achieved, reoccurring symptoms can be controlled using an on-demand regimen of 20 mg once daily, when required. A switch to continuous therapy may be considered in case satisfactory symptom control cannot be maintained with on-demand treatment. Long-term management and prevention of relapse in reflux oesophagitis For long-term management, a maintenance dose of one gastro-resistant קרא את המסמך השלם